Rozibafusp Alfa

DB19233InvestigationalProtein Based Therapies

Rozibafusp Alfa is under investigation in clinical trial NCT04058028 (Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)).

Mechanism: Pharmacologically active on Tumor necrosis factor ligand superfamily member 13B and Inducible T-cell costimulator
Curator reviewed
Also known as: Anti-b7rp-1mab/baff · IMMUNOGLOBULIN G2-KAPPA, ANTI-(HUMAN INDUCIBLE COSTIMULATOR (ICOS) LIGAND PROTEIN) HUMAN MONOCLONAL ANTIBODY, FUSED WITH TWO COPIES OF A TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13B (TNFSF13B, B-CELL ACTIVATING FACTOR, BAFF)-BINDING PEPTIDE, GLYCO
Code names: AMG-570 · MEDI-0700

Resolves to

Compound

UNIIO9YF5SN7KLCAS2143449-47-0

Targets

Q9Y275TNFSF13BQ9Y6W8ICOS

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rozibafusp Alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account